Tenaya Therapeutics, Inc. (TNYA)

Market Cap	158.00M +119.7%
Revenue (ttm)	225,000
Net Income	-83.01M
EPS	-0.46
Shares Out	217.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,521,820
Open	0.7600
Previous Close	0.7721
Day's Range	0.7100 - 0.7600
52-Week Range	0.5207 - 2.3500
Beta	2.82
Analysts	Strong Buy
Price Target	4.00 (+449.38%)
Earnings Date	May 6, 2026

About TNYA

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: TNYA
• Website: https://www.tenayatherapeutics.com

Analyst Summary

According to 8 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 449.38% from the latest price.

Price Target

$4.0

(449.38% upside)

Analyst Consensus: Strong Buy